SI1456380T1 - Smad inhibitorji za zdravljenje cns bolezni - Google Patents

Smad inhibitorji za zdravljenje cns bolezni

Info

Publication number
SI1456380T1
SI1456380T1 SI200230992T SI200230992T SI1456380T1 SI 1456380 T1 SI1456380 T1 SI 1456380T1 SI 200230992 T SI200230992 T SI 200230992T SI 200230992 T SI200230992 T SI 200230992T SI 1456380 T1 SI1456380 T1 SI 1456380T1
Authority
SI
Slovenia
Prior art keywords
treatment
cns diseases
smad7 inhibitors
diseases
disease
Prior art date
Application number
SI200230992T
Other languages
English (en)
Inventor
Andreas Steinbrecher
Gerhard Giegerich
Ingo Kleiter
Markus Horn
Rainer Apfel
Roland Kreutzer
Stefan Limmer
Hans-Peter Vornlocher
Original Assignee
Giuliani Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giuliani Int Ltd filed Critical Giuliani Int Ltd
Publication of SI1456380T1 publication Critical patent/SI1456380T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI200230992T 2001-11-02 2002-10-31 Smad inhibitorji za zdravljenje cns bolezni SI1456380T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01126140 2001-11-02
EP02790321A EP1456380B1 (en) 2001-11-02 2002-10-31 Smad7 inhibitors for the treatment of cns diseases
PCT/EP2002/012221 WO2003037368A2 (en) 2001-11-02 2002-10-31 Smad7 inhibitors for the treatment of cns diseases

Publications (1)

Publication Number Publication Date
SI1456380T1 true SI1456380T1 (sl) 2012-11-30

Family

ID=8179155

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200230992T SI1456380T1 (sl) 2001-11-02 2002-10-31 Smad inhibitorji za zdravljenje cns bolezni

Country Status (10)

Country Link
US (2) US7700572B2 (sl)
EP (1) EP1456380B1 (sl)
AT (1) ATE554169T1 (sl)
AU (1) AU2002363182A1 (sl)
CY (1) CY1112932T1 (sl)
DK (1) DK1456380T3 (sl)
ES (1) ES2388968T3 (sl)
PT (1) PT1456380E (sl)
SI (1) SI1456380T1 (sl)
WO (1) WO2003037368A2 (sl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2388968T3 (es) * 2001-11-02 2012-10-22 Giuliani International Limited Inhibidores de Smad7 para el tratamiento de enfermedades del SNC
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
SG10201607710UA (en) 2008-03-17 2016-11-29 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
EP3121280A1 (en) 2008-11-13 2017-01-25 Nogra Pharma Limited Antisense compositions and methods of making and using same
WO2010065917A1 (en) * 2008-12-05 2010-06-10 The Regents Of The University Of California Methods of treating neurological disorders
CN105861446B (zh) 2009-10-16 2021-10-01 斯克里普斯研究所 多能细胞的诱导
ES2624780T3 (es) 2010-03-31 2017-07-17 The Scripps Research Institute Reprogramación de células
JP6182456B2 (ja) 2010-12-22 2017-08-23 フェイト セラピューティクス，インコーポレイテッド 単細胞選別のための細胞培養プラットホームおよびｉＰＳＣの再プログラミングの増強
ES2392862B1 (es) * 2011-06-02 2013-11-05 Fundación Para La Investigación Biomédica Del Hospital Universitario Ramón Y Cajal Tgf-beta y/o smad3 como marcadores de diagnóstico y/o pronóstico de alfa-sinucleinopatías
US9791442B2 (en) 2011-09-15 2017-10-17 Nogra Pharma Limited Methods of monitoring responsiveness to anti-SMAD7 therapy
AU2013249191B2 (en) * 2012-04-18 2019-01-03 Nogra Pharma Limited Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
EP3114214B1 (en) 2014-03-04 2023-11-01 Fate Therapeutics, Inc. Improved reprogramming methods and cell culture platforms
KR20170005058A (ko) 2014-05-09 2017-01-11 노그라 파마 리미티드 염증성 장 질환을 치료하는 방법
US10023879B2 (en) 2014-06-04 2018-07-17 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells
AU2015332624A1 (en) 2014-10-17 2017-05-04 Nogra Pharma Limited Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
CN114058582A (zh) 2015-01-26 2022-02-18 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
SG11201802957PA (en) 2015-10-16 2018-05-30 Fate Therapeutics Inc Platform for the induction & maintenance of ground state pluripotency
CA3003152A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CN108368520B (zh) 2015-11-04 2023-01-17 菲特治疗公司 多能细胞的基因组工程改造
US11162097B2 (en) 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
WO2019051173A1 (en) * 2017-09-08 2019-03-14 Ionis Pharmaceuticals, Inc. MODULATORS OF SMAD7 EXPRESSION

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096722A (en) * 1990-08-14 2000-08-01 Isis Pharmaceuticals Inc. Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
AU678769B2 (en) * 1992-07-27 1997-06-12 Hybridon, Inc. Oligonucleotide alkylphosphonothioates
US6884787B2 (en) * 2001-07-14 2005-04-26 Isis Pharmaceuticals, Inc. Antisense modulation of transforming growth factor-beta 3 expression
CA2148465C (en) * 1992-11-06 1999-11-02 Minenobu Okayama Oral pharmaceutical preparation releasable in the lower digestive tract
US20020177568A1 (en) * 1992-12-07 2002-11-28 Stinchcomb Dan T. Enzymatic nucleic acid treatment of diseases or conditions related to levels of NF-kappa B
JP3555952B2 (ja) * 1993-04-30 2004-08-18 バイオグノスティック・ゲゼルシャフト・フュア・バイオモレキュラーレ・ダイアグノスティック・ミット・ベシュレンクテル・ハフツング トランスフォーミング成長因子−β（ＴＧＦ‐β）の免疫抑制効果の治療用アンチセンス−オリゴヌクレオチド類
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
JP2001521365A (ja) * 1996-02-16 2001-11-06 ミレニウム ファーマシューティカルズ，インコーポレーテッド 心臓血管病の治療および診断のための組成物並びに方法
US5783566A (en) * 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6051381A (en) 1996-12-11 2000-04-18 Kornacker; Michael G. Prokaryotic two-hybrid system
JPH10295381A (ja) * 1997-04-23 1998-11-10 Seibutsu Bunshi Kogaku Kenkyusho:Kk 新規シグナル伝達因子、およびそれをコードする遺伝子
US6251628B1 (en) * 1997-05-20 2001-06-26 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding Smad7
WO1999001579A1 (en) * 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
JPH11335269A (ja) * 1998-05-19 1999-12-07 Hisamitsu Pharmaceut Co Inc 遺伝子関連医薬の経口投与固形製剤
AU4869399A (en) 1998-07-10 2000-02-01 Curagen Corporation Interaction of human beta amyloid precursor protein (beta-app) with human lon-protease like protein (hslon)
US6479465B2 (en) * 1999-03-24 2002-11-12 The United States Of America As Represented By The Department Of Health And Human Services Methods of treating colitis using STAT-4 anti-sense oligonucleotides
US6159697A (en) * 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
US20020147140A1 (en) * 2000-01-31 2002-10-10 Rosen Craig A. Nucleic acids, proteins, and antibodies
AU2001241751B2 (en) * 2000-02-23 2005-09-01 Tel Aviv Sourasky Medical Center Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
AU2001249345A1 (en) * 2000-03-21 2001-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
AUPR638101A0 (en) * 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
ES2388968T3 (es) * 2001-11-02 2012-10-22 Giuliani International Limited Inhibidores de Smad7 para el tratamiento de enfermedades del SNC
JP2003135075A (ja) * 2001-11-05 2003-05-13 Research Association For Biotechnology 新規な全長ｃＤＮＡ
WO2004053099A2 (en) * 2002-12-10 2004-06-24 The Scripps Research Institute A method for treatment of drug addiction and for screening of pharmaceutical agents therefor
ITRM20030149A1 (it) * 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US20040265833A1 (en) * 2003-06-23 2004-12-30 Cathy Lofton-Day Methods and nucleic acids for the analysis of colorectal cell proliferative disorders
AU2005218759B2 (en) * 2004-02-27 2009-07-16 Antisense Pharma Gmbh Pharmaceutical composition
US20080312093A1 (en) * 2005-11-04 2008-12-18 Johji Inazawa Method for detecting cancer and a method for suppressing cancer
US20110152352A1 (en) * 2008-06-10 2011-06-23 Tufts University Smad proteins control drosha-mediated mirna maturation
US8110355B2 (en) * 2009-02-20 2012-02-07 GenRemedy, LLC Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis

Also Published As

Publication number Publication date
AU2002363182A1 (en) 2003-05-12
US20050119203A1 (en) 2005-06-02
WO2003037368A2 (en) 2003-05-08
ES2388968T3 (es) 2012-10-22
EP1456380A2 (en) 2004-09-15
US20110207795A1 (en) 2011-08-25
US7700572B2 (en) 2010-04-20
CY1112932T1 (el) 2016-04-13
WO2003037368A3 (en) 2004-03-11
ATE554169T1 (de) 2012-05-15
DK1456380T3 (da) 2012-07-30
EP1456380B1 (en) 2012-04-18
PT1456380E (pt) 2012-07-23

Similar Documents

Publication Publication Date Title
SI1456380T1 (sl) Smad inhibitorji za zdravljenje cns bolezni
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
HK1057899A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
HK1087702A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
MXPA04005790A (es) Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona.
WO2003106381A3 (en) ADAM 10 HUMAN INHIBITORS
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
BR0115411A (pt) Combinações sinergìsticas compreendendo um inibidor de renina para doenças cardiovasculares
DE60229530D1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
GB0111186D0 (en) Novel compounds
DE50109156D1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
MY124786A (en) Bis-arylsulfones
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
DK0989973T3 (da) Chalconer med antiproliferativ aktivitet
BG105953A (en) Method for treating copd
MXPA02011921A (es) Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona.
ME00550B (me) Korišćenje il-18 inhibitora za lećenje ili prevenciju povreda cns
IL161116A0 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
WO2002057211A8 (en) Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (adp-ribose) glycohydrolase, and methods for their use
WO2003011309A3 (de) Verwendung einer calciumhaltigen pharmazeutischen zusammensetzung zur behandlung von hypercholesterinämie
MXPA06002778A (es) Combinacion de inhibidores de recaptacion de serotonina e inhibidores de recaptacion de norepinefrina.
EP1201764A3 (en) Assays for identifying phosphatase inhibitors